Histone Deacetylase Inhibitors Downregulate CCR4 Expression and Decrease Mogamulizumab Efficacy in CCR4-positive Mature T-Cell Lymphomas

Haematologica - Italy
doi 10.3324/haematol.2017.177279
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Ferrata Storti Foundation (Haematologica)

Related search

Targeting Chemokine Receptor CCR4 in Adult T-Cell Leukemia-Lymphoma and Other T-Cell Lymphomas

Current Hematologic Malignancy Reports
Cancer ResearchOncologyHematology
2012English

CCR4-dependent Regulatory T Cell Function in Inflammatory Bowel Disease

Journal of Experimental Medicine
MedicineAllergyImmunology
2007English

CCR4-bearing T Cells Participate in Autoimmune Diabetes

Journal of Clinical Investigation
Medicine
2002English

Anti-Ccr4 Monoclonal Antibody KW-0761 (Mogamulizumab) or Investigator's Choice in Subjects With Relapsed or Refractory Adult T-Cell Leukemia-Lymphoma (ATL)

Retrovirology
VirologyInfectious Diseases
2015English

Rapalog Combined With CCR4 Antagonist Improves Anticancer Vaccines Efficacy

International Journal of Cancer
Cancer ResearchOncology
2018English

Gene Expression-Based Prediction of Myeloma Cell Sensitivity to Histone Deacetylase Inhibitors

British Journal of Cancer
Cancer ResearchOncology
2013English

Histone Deacetylase Inhibitors Modulate Interleukin 6-Dependent CD4+T Cell Polarizationin Vitroandin Vivo

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2014English

Inhibitors of Histone-Deacetylase

Journal of Applied Biomedicine
GeneticsMolecular BiologyPharmacologyBiochemistryBiological SciencesToxicologyMedicineAgriculturalNeurosciencePharmaceutics
2005English

Pharmacogenomics and Histone Deacetylase Inhibitors

Pharmacogenomics
Molecular MedicineGeneticsPharmacology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy